Lyell Immunopharma, Inc.
LYEL
$8.69
-$0.89-9.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 301.18M | 370.53M | 440.55M | 491.12M | 526.30M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 8.00M | 9.07M | 9.50M | 8.71M | 7.87M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 309.18M | 379.59M | 450.05M | 499.82M | 534.17M |
|
|
|||||
| Total Current Assets | 309.18M | 379.59M | 450.05M | 499.82M | 534.17M |
| Net Property, Plant & Equipment | 67.77M | 72.94M | 124.71M | 130.79M | 136.53M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 4.91M | 6.31M | 5.35M | 4.53M | 4.52M |
| Total Assets | 429.80M | 490.86M | 619.22M | 654.14M | 694.22M |
|
|
|||||
| Total Accounts Payable | 3.73M | 5.37M | 3.60M | 4.20M | 4.90M |
| Total Accrued Expenses | 22.93M | 29.37M | 21.88M | 18.77M | 18.25M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 8.24M | 7.97M | 7.13M | 6.90M | 6.67M |
| Total Finance Division Other Current Liabilities | 6.39M | 11.08M | 907.00K | 1.01M | 2.54M |
| Total Other Current Liabilities | 6.39M | 11.08M | 907.00K | 1.01M | 2.54M |
| Total Current Liabilities | 41.29M | 53.79M | 33.51M | 30.88M | 32.35M |
|
|
|||||
| Total Current Liabilities | 41.29M | 53.79M | 33.51M | 30.88M | 32.35M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 48.85M | 50.99M | 51.44M | 53.32M | 55.16M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 3.14M | 3.25M | 3.57M | 3.44M | 3.55M |
| Total Liabilities | 93.28M | 108.04M | 88.52M | 87.64M | 91.06M |
|
|
|||||
| Common Stock & APIC | 1.73B | 1.73B | 1.68B | 1.68B | 1.67B |
| Retained Earnings | -1.40B | -1.35B | -1.15B | -1.11B | -1.06B |
| Treasury Stock & Other | 158.00K | 291.00K | 760.00K | -397.00K | -404.00K |
| Total Common Equity | 336.52M | 382.82M | 530.70M | 566.50M | 603.16M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 336.52M | 382.82M | 530.70M | 566.50M | 603.16M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 336.52M | 382.82M | 530.70M | 566.50M | 603.16M |
|
|
|||||